When an individual suffers a heart attack (also known as a Myocardial Infarction), the heart muscle can be deprived of blood and oxygen. When this occurs, the affected heart muscle is damaged and can deteriorate. Human heart muscle does not have the ability to regenerate like other muscles in the body. MicroRNA (miR) technology offers the promise of inducing proliferation of heart muscle cells, known as Cardiomyocytes. In preclinical animal models the proliferation of Cardiomyocytes prevented fibrous remodeling of damaged heart muscle. This a helps restore the ability of the heart to properly pump blood throughout the body.
Healthy heart muscles contract in a synchronized pattern to pump blood throughout the body. When human heart muscle is damaged, it is replaced by scar tissue. The damaged and scarred tissue can no longer effectively pump blood. This condition leaves a patient more susceptible to a future heart attack and heart failure.
Vision
Prolifagen’s vision is to be the leader in providing solutions for the regeneration of heart muscle that has been damaged following a heart attack. We are committed to advancing the science of miR technology and providing doctors and patients with a solution to a significant unmet need and economic burden.
Scientific Advancement
Prolifagen is advancing the science of miR with ongoing research that offers the promise of solving a significant unmet need…Regenerating heart muscle that has been damaged following a heart attack. Our team of distinguished scientists has demonstrated the potential of miR to help patients recover from a heart attack. We will continue to push the boundaries of the current paradigm in heart medicine through additional scientific research. Our goal is to provide doctors with an effective solution to the problem of regenerating heart muscle that has been irreparably damaged by a heart attack.